Dashboard
1
Poor Management Efficiency with a low ROCE of 471.21%
- The company has been able to generate a Return on Capital Employed (avg) of 471.21% signifying low profitability per unit of total capital (equity and debt)
2
The company is Net-Debt Free
3
Poor long term growth as Net Sales has grown by an annual rate of -28.44% and Operating profit at -171.09% over the last 5 years
4
Risky -
5
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 3,970 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-0.35
-9.81%
0.67
Revenue and Profits:
Net Sales:
256 Million
(Quarterly Results - Mar 2026)
Net Profit:
-99 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-36.7%
0%
-36.7%
6 Months
-41.41%
0%
-41.41%
1 Year
-30.74%
0%
-30.74%
2 Years
-55.79%
0%
-55.79%
3 Years
-83.03%
0%
-83.03%
4 Years
-82.92%
0%
-82.92%
5 Years
-73.98%
0%
-73.98%
Zhejiang Orient Gene Biotech Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-28.44%
EBIT Growth (5y)
-171.09%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.40
Sales to Capital Employed (avg)
0.12
Tax Ratio
4.11%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
122.90%
ROE (avg)
28.64%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.60
EV to EBIT
-2.42
EV to EBITDA
-3.33
EV to Capital Employed
0.38
EV to Sales
1.44
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-15.73%
ROE (Latest)
-9.81%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
256.30
275.60
-7.00%
Operating Profit (PBDIT) excl Other Income
-88.20
-286.50
69.21%
Interest
2.50
2.40
4.17%
Exceptional Items
3.00
-6.60
145.45%
Consolidate Net Profit
-98.70
-366.20
73.05%
Operating Profit Margin (Excl OI)
-344.00%
-1,243.00%
89.90%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -7.00% vs 2.57% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 73.05% vs -541.33% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
944.70
827.10
14.22%
Operating Profit (PBDIT) excl Other Income
-271.80
-534.70
49.17%
Interest
12.20
20.60
-40.78%
Exceptional Items
-175.20
-70.90
-147.11%
Consolidate Net Profit
-597.40
-568.80
-5.03%
Operating Profit Margin (Excl OI)
-519.90%
-922.60%
40.27%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 14.22% vs 1.01% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -5.03% vs -35.98% in Dec 2024
About Zhejiang Orient Gene Biotech Co., Ltd. 
Zhejiang Orient Gene Biotech Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






